• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Penumbra Inc.

    3/27/26 11:22:11 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care
    Get the next $PEN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 8)


    Penumbra Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    70975L107

    (CUSIP Number)
    03/13/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    70975L107


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:   On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Penumbra Inc
    (b)Address of issuer's principal executive offices:

    1 Penumbra Place, Alameda, CA, 94502
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd.,, Malvern, PA, 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    0
    (b)Percent of class:

    0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:03/27/2026
    Get the next $PEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PEN

    DatePrice TargetRatingAnalyst
    12/18/2025$370.00Neutral → Overweight
    Analyst
    12/11/2025$350.00Neutral → Buy
    Citigroup
    11/18/2025$15.00Underweight
    Wells Fargo
    10/8/2025$326.00Hold → Buy
    Needham
    9/2/2025$300.00Outperform
    Evercore ISI
    3/14/2025$320.00Buy
    BofA Securities
    1/21/2025$305.00Buy
    UBS
    12/17/2024$275.00Outperform
    Oppenheimer
    More analyst ratings

    $PEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Penumbra upgraded by Analyst with a new price target

    Analyst upgraded Penumbra from Neutral to Overweight and set a new price target of $370.00

    12/18/25 8:43:06 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Penumbra upgraded by Citigroup with a new price target

    Citigroup upgraded Penumbra from Neutral to Buy and set a new price target of $350.00

    12/11/25 8:45:41 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Wells Fargo initiated coverage on Penumbra with a new price target

    Wells Fargo initiated coverage of Penumbra with a rating of Underweight and set a new price target of $15.00

    11/18/25 9:40:08 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    $PEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Narayan Shruthi covered exercise/tax liability with 117 shares, decreasing direct ownership by 0.38% to 30,755 units (SEC Form 4)

    4 - Penumbra Inc (0001321732) (Issuer)

    3/17/26 7:33:39 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    EVP, Gen. Counsel & Secretary Roberts Johanna covered exercise/tax liability with 186 shares, decreasing direct ownership by 0.28% to 67,298 units (SEC Form 4)

    4 - Penumbra Inc (0001321732) (Issuer)

    3/17/26 7:32:44 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Yuen Maggie covered exercise/tax liability with 186 shares, decreasing direct ownership by 1% to 18,167 units (SEC Form 4)

    4 - Penumbra Inc (0001321732) (Issuer)

    3/17/26 7:32:14 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    $PEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    ALAMEDA, Calif., Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2025. Financial Highlights:Revenue of $385.4 million for the fourth quarter of 2025, an increase of 22.1% or 20.9% in constant currency1, compared to the fourth quarter of 2024.Revenue of $1,403.7 million for the full year 2025, an increase of 17.5% or 16.9% in constant currency1, compared to the full year 2024.U.S. Thrombectomy revenue of $203.1 million for the fourth quarter

    2/25/26 1:00:00 PM ET
    $BSX
    $PEN
    Medical/Dental Instruments
    Health Care

    Boston Scientific announces results for fourth quarter and full year 2025

    MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational1 basis and 12.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $672 million or $0.45 per share (EPS), compared to $566 million or $0.38 per share a year ago, and achieved adjusted3 EPS of $0.80 for the period, compared to $0.70 a year ago.

    2/4/26 6:30:00 AM ET
    $BSX
    $PEN
    Medical/Dental Instruments
    Health Care

    Boston Scientific announces agreement to acquire Penumbra, Inc.

    Acquisition to expand Boston Scientific's cardiovascular portfolio and further address increasing prevalence of vascular diseases Provides scaled entry into mechanical thrombectomy and neurovascular, key strategic adjacencies Conference call at 8:00 a.m. ET to discuss details of the transaction MARLBOROUGH, Mass. and ALAMEDA, Calif., Jan. 15, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) and Penumbra, Inc., (NYSE:PEN) today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock transaction that values Penumbra at $374 per share, reflecting an enterprise value of approximately $14.5 billion.i

    1/15/26 7:00:00 AM ET
    $BSX
    $PEN
    Medical/Dental Instruments
    Health Care

    $PEN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Penumbra Inc.

    SCHEDULE 13G/A - Penumbra Inc (0001321732) (Subject)

    3/27/26 11:22:11 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    SEC Form 425 filed by Penumbra Inc.

    425 - Penumbra Inc (0001321732) (Subject)

    3/3/26 4:57:10 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Penumbra Inc.

    10-K - Penumbra Inc (0001321732) (Filer)

    2/25/26 1:27:55 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    $PEN
    Leadership Updates

    Live Leadership Updates

    View All

    New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile

    Survey Conducted by the Get Out the Clot Campaign, an Initiative Focused on Identifying and Closing Gaps in Patient Care for Blood Clots ALAMEDA, Calif., Sept. 9, 2025 /PRNewswire/ -- The American Venous Forum (AVF), International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra (NYSE:PEN), The PERT Consortium® and Society for Vascular Medicine (SVM), which have come together to form the Get Out the Clot campaign, today announced findings from a new survey assessing the current state of venous thromboembolism (VTE) care, also known as blood clots in the body. Get Out the Clot is a collaborative educational initiative to help identify gaps in patient

    9/9/25 9:00:00 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Get Out the Clot Campaign Brings Together Leaders and Experts to Improve Patient Care for Venous Thromboembolism

    Campaign is led by prominent medical societies to minimize discrepancies in treating blood clot conditions, such as in pulmonary embolism, where there are often delays in care (up to 26% of patients in one study) and misdiagnosis (up to 53% of patients in one study)1,2 ALAMEDA, Calif., Oct. 10, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE:PEN), The PERT Consortium™ and Society for Vascular Medicine (SVM) today announced the launch of the Get Out the Clot campaign in advance of World Thrombosis Day on October 13. The campaign is a collaborative educational initiative focused on identifying gaps i

    10/10/24 9:00:00 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Omniscient Neurotechnology Appoints Two New Members to Its Board of Directors

    SYDNEY, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health, today announced the appointment of Barbara Nelson and Surbhi Sarna to its board of directors. Both appointees are visionaries across the biotech, healthcare and technology industries and bring a unique perspective to the company's corporate strategy and growth. They, along with the existing board members, will strategically guide Omniscient as it develops products that unlock new insights into advanced brain care. "Omniscient is a global leader in connectomics, but we have much work ahead of us to scale to our full potential," said Chairma

    10/24/22 8:30:00 AM ET
    $BLZE
    $GSIT
    $PEN
    Computer Software: Prepackaged Software
    Technology
    Semiconductors
    Medical/Dental Instruments

    $PEN
    Financials

    Live finance-specific insights

    View All

    Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    ALAMEDA, Calif., Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2025. Financial Highlights:Revenue of $385.4 million for the fourth quarter of 2025, an increase of 22.1% or 20.9% in constant currency1, compared to the fourth quarter of 2024.Revenue of $1,403.7 million for the full year 2025, an increase of 17.5% or 16.9% in constant currency1, compared to the full year 2024.U.S. Thrombectomy revenue of $203.1 million for the fourth quarter

    2/25/26 1:00:00 PM ET
    $BSX
    $PEN
    Medical/Dental Instruments
    Health Care

    Boston Scientific announces results for fourth quarter and full year 2025

    MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational1 basis and 12.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $672 million or $0.45 per share (EPS), compared to $566 million or $0.38 per share a year ago, and achieved adjusted3 EPS of $0.80 for the period, compared to $0.70 a year ago.

    2/4/26 6:30:00 AM ET
    $BSX
    $PEN
    Medical/Dental Instruments
    Health Care

    Boston Scientific announces agreement to acquire Penumbra, Inc.

    Acquisition to expand Boston Scientific's cardiovascular portfolio and further address increasing prevalence of vascular diseases Provides scaled entry into mechanical thrombectomy and neurovascular, key strategic adjacencies Conference call at 8:00 a.m. ET to discuss details of the transaction MARLBOROUGH, Mass. and ALAMEDA, Calif., Jan. 15, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) and Penumbra, Inc., (NYSE:PEN) today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock transaction that values Penumbra at $374 per share, reflecting an enterprise value of approximately $14.5 billion.i

    1/15/26 7:00:00 AM ET
    $BSX
    $PEN
    Medical/Dental Instruments
    Health Care

    $PEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

    SC 13G/A - Penumbra Inc (0001321732) (Subject)

    11/14/24 1:22:36 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

    SC 13G/A - Penumbra Inc (0001321732) (Subject)

    11/12/24 12:53:28 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Penumbra Inc.

    SC 13G - Penumbra Inc (0001321732) (Subject)

    2/14/24 10:03:02 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care